Current practices and guidelines for clinical next-generation sequencing oncology testing

Abstract

Next-generation sequencing (NGS) has been rapidly integrated into molecular pathology, dramatically increasing the breadthgenomic of information available to oncologists and their patients. This review will explore the ways in which this new technologyis currently applied to bolster care for patients with solid tumors and hematological malignancies, focusing on practices andguidelines for assessing the technical validity and clinical utility of DNA variants identified during clinical NGS oncology testing.